Search Medical Condition
Please enter condition
Please choose location

Avon, Indiana Clinical Trials

A listing of Avon, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (32) clinical trials

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Phase

0.0 miles

Learn More »

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes With a FRC Extension Period

The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety followup period. Maximum duration for FRC patients will be approximately 55 weeks: an up to ...

Phase

0.0 miles

Learn More »

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs ≥ 30 kg/m2) and stage ...

Phase

0.0 miles

Learn More »

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

Fedovapagon is a selective vasopressin V2 receptor (V2R) agonist that has an antidiuretic effect through stimulation of V2 receptors in the kidney and is being developed for the treatment of nocturia. Nocturia, defined as the complaint that the individual has to wake at night one or more times to void, ...

Phase

0.01 miles

Learn More »

Evaluate the Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects (Ages 2 to 11 Years Inclusive) With Mild to Moderate Plaque Psoriasis.

This is a multicenter, open-label, Phase 1 study in a total of 75 pediatric subjects, ages 2 to 11 years, inclusive, with mild or moderate plaque psoriasis. The study will enroll sufficient subjects with plaque psoriasis and an ISGA score of mild to moderate (score of 2 or 3) at ...

Phase

4.05 miles

Learn More »